CA-125 Testing: Ovarian Cancer Marker Reality Check
Content last reviewed 2026-09-12 · Educational information — not medical advice
Quick answer
CA-125 screens ovarian-cancer TREATMENT response excellently but fails as standalone DIAGNOSIS — benign conditions (endometriosis, fibroids, menstruation, pregnancy) elevate it routinely. Its power lives in longitudinal trending and multimodal HE4/RMI combinations.
The specificity problem stated numerically
Elevated CA-125 in premenopausal women with pelvic symptoms: malignancy probability stays minority-tier — endometriosis/uterine-leiomyoma/pelvic-inflammatory processes explain most elevations. Postmenopausal elevations sharpen suspicion considerably (risk-of-malignancy-index incorporates menopausal status deliberately).
Where CA-125 shines
- Known-ovarian-cancer monitoring: treatment-response tracking and recurrence surveillance (rising trends preceding radiographic visibility)
- Symptomatic-adnexal-mass triage: RMI (CA-125 × menopausal-score × ultrasound-score) stratifies surgical urgency appropriately
- High-risk-genetics surveillance: BRCA carriers integrate CA-125 with transvaginal ultrasound (imperfectly — prophylactic surgery remains definitive)
HE4 and multimer panels
HE4 (human epididymis protein) complements CA-125's weaknesses — ROMA algorithm (Risk of Ovarian Malignancy Algorithm) combines CA-125+HE4+menopausal-status outperforming either alone for mass-triage. Still screening-invalid: asymptomatic-population deployment floods false-positive channels harmfully.
Symptoms that SHOULD prompt evaluation
Persistent bloating, pelvic/abdominal pain, early satiety, urinary urgency — the notorious 'ovarian whisper' quartet lasting >2-4 weeks deserves pelvic examination ± ultrasound ± CA-125 in combination. Symptom-triggered testing validates; population screening doesn't.
Order this test online
Direct-access laboratory testing — no appointment or doctor visit required. Results delivered as secure PDFs.
We may earn a commission when you order through partner links. Educational content only — never a substitute for professional medical advice.
Frequently asked questions
My CA-125 was 68 — is it cancer?
Premenopausal with symptoms? Endometriosis/fibroids dominate explanations. Postmenopausal? Sharpened vigilance justified with imaging partnership. Number-alone never diagnoses.
Should healthy women screen annually?
USPSTF recommends AGAINST ovarian-cancer screening asymptomatic-average-risk women — harms (surgeries-from-false-positives) outweighed benefits in trials.